Divine Aleru, Microbiome Signatures Research Coordinator

Premenstrual Dysphoric Disorder (PMDD) is a severe mood disorder linked to hormonal and neurochemical changes. Emerging research highlights the gut microbiome’s role in symptom modulation, opening new avenues for microbiome-targeted treatments alongside traditional therapies.

This review discusses the toxicological impact of heavy metals like arsenic, cadmium, and mercury on human health, particularly their interaction with proteins and enzymes, leading to various disorders and potential carcinogenesis. Detoxification strategies and the importance of environmental cleanup are also highlighted.

The study highlights the cooperation between the PbrA efflux pump and PbrB phosphatase in the detoxification of lead, uncovering a novel mechanism for lead resistance in Cupriavidus metallidurans. This research suggests potential bioremediation applications and deeper insights into microbial heavy metal resistance mechanisms.

This study sheds light on the molecular mechanisms through which Cupriavidus metallidurans CH34 regulates lead resistance, highlighting the role of the PbrR protein and its interaction with the PpbrA promoter in response to Pb(II).

This study demonstrates that lead exposure disrupts the gut microbiome, reducing microbial diversity and impairing key metabolic pathways related to vitamin E, bile acids, nitrogen metabolism, and energy metabolism. These disruptions may contribute to lead toxicity and associated diseases.

This review maps mechanisms and taxa underlying lead bioremediation by bacteria, linking microbial toolkits (EPS, phosphatases, sulfate reducers, PIB-ATPases, metallothioneins) to field performance and clinical microbiome relevance, and guiding signature curation and remediation design.

The review examines the neurotoxic effects of lead exposure, focusing on mechanisms such as ion mimicry, mitochondrial dysfunction, and neuroinflammation. It emphasizes the long-term impact of lead on cognitive function and behavior and discusses biomarkers for assessing lead exposure and its effects on the brain.

This review explores the molecular mechanisms of lead neurotoxicity, focusing on ion mimicry, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The findings emphasize the long-term cognitive and behavioral effects of lead exposure, with implications for clinical intervention and microbiome-related research.

The review highlights the connection between lead exposure and osteoporosis risk in post-menopausal women, showing how lead release during bone turnover contributes to health complications. Strategies to reduce bone resorption during menopause can mitigate lead-related risks and improve health outcomes.

CDC lowered the pediatric BLRV to 3.5 µg/dL, enabling earlier action, clarifying disparities, and setting exposure tiers that should guide microbiome signature curation at contemporary low BLLs.

Meta-analysis shows ALAD polymorphism and lead interactions: ALAD2 raises BLL in workers, lowers chelatable lead, and slightly improves heme indices; bone lead is unchanged.

Clinician summary of prenatal lead exposure and gut microbiome links at age 9–11 in PROGRESS: negative mixture effects, trimester-specific taxa shifts, and a potential second-trimester sensitivity window.

A clinician-focused review updates present-day lead exposure risks and microbiome implications, contrasting older population metrics with SPHERL’s prospective data and outlining how exposure tiers, co-exposures, and confounding shape credible microbiome–lead signatures.

NICE guidance recommends diagnosing menopause in women over 45 clinically, not with lab tests, while FSH measurement is reserved for suspected POI in women under 40, streamlining care and reducing unnecessary testing in clinical biochemistry laboratories.

Hormone Replacement Therapy (HRT) is one of the most effective treatments for women experiencing the symptoms of menopause, particularly vasomotor symptoms such as hot flashes and night sweats. But its benefits go beyond just symptom management. HRT can also play a key role in improving vaginal health by alleviating dryness and discomfort, which are common complaints among women in menopause. Additionally, it helps prevent bone loss, significantly reducing the risk of osteoporosis and fractures, which are more common after menopause. Despite its many benefits, HRT is not one-size-fits-all; it’s essential to tailor treatment based on individual health profiles, taking into account the risks like breast cancer, blood clots, and heart disease that come with prolonged use.

Ospemifene is an effective and safe treatment for menopausal vaginal dryness and dyspareunia, particularly in women with contraindications for estrogen therapy. It improves vaginal health without significantly affecting systemic hormone levels, providing an alternative treatment for genitourinary syndrome of menopause.

Ospemifene (60 mg/day) significantly reduces dyspareunia and improves vaginal health in postmenopausal women with vulvar and vaginal atrophy. It offers a non-estrogenic treatment option, especially for women who cannot use traditional hormone therapies.

This study examined the systemic and local effects of vaginal dehydroepiandrosterone (DHEA) in postmenopausal women, particularly those with a history of breast or gynecologic cancer. It evaluated the impact of vaginal DHEA on hormone concentrations, markers of bone formation, and vaginal cytology, including pH and maturation index. The study aimed to assess […]

This review underscores the importance of nutrition in managing menopausal symptoms and preventing chronic diseases. It highlights key nutrients such as calcium, vitamin D, and protein and promotes a balanced diet and regular physical activity as integral parts of menopausal health management.

This study reveals that higher levels of physical activity, especially during leisure time, are linked to reduced severity of menopausal symptoms, particularly urogenital and somato-vegetative issues. It suggests incorporating physical activity into the management plan for menopausal women, particularly postmenopausal women.

This review and meta-analysis demonstrate that psychological interventions, such as CBT, MBT, and BT, can significantly reduce hot flash bother and menopausal symptoms. These findings are especially relevant for breast cancer survivors, offering a safe, non-hormonal alternative to HRT.

Veozah (fezolinetant) is an effective non-hormonal treatment for menopause-related vasomotor symptoms. It works by targeting the neurokinin 3 receptor and offers a promising alternative to estrogen therapy with minimal side effects, making it suitable for women with contraindications to hormone treatments.

This study demonstrates that gabapentin 300 mg/day is as effective as estrogen 0.625 mg/day for reducing hot flashes in post-menopausal women. It provides a viable non-hormonal alternative with fewer side effects, making it a good option for women unable or unwilling to take estrogen.

This review confirms that SSRIs and SNRIs, particularly paroxetine and venlafaxine, are effective for managing hot flashes in menopausal women. These therapies provide an alternative to hormone replacement therapy, with minimal side effects and considerations for women with specific health concerns, like hypertension or a history of breast cancer.